The global splenomegaly therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). Splenomegaly is a medical condition in which the spleen enlarges as a result of a variety of medical conditions. The spleen stores white and red blood cells and aids the immune system by producing various antibodies. The spleen is important for keeping the immune system healthy. The spleen filters bacteria that have been coated with antibodies, processes old red blood cells, and recycles iron in haemoglobin. Infectious infections, liver disorders, cystic fibrosis, rheumatoid arthritis, leukaemia, Hodgkin's disease, and splenic tumours are all medical ailments that can cause splenomegaly. Treatment for splenomegaly entails addressing the underlying causes of the condition.

The increased frequency of underlying causes of splenomegaly, such as autoimmune disorders, viral diseases, and liver cancer, is driving the global splenomegaly therapeutics market. Every year, more than 17 million people die around the globe as a result of infectious diseases, according to the World Health Organization (WHO). In emerging countries with large populations, such as India, China, Brazil, Mexico, and Africa, infectious diseases are quite common. Furthermore, increased incidences of autoimmune illnesses in western countries are expected to drive the splenomegaly therapeutics market in these countries throughout the forecast period. For instance, rheumatoid arthritis has a global incidence rate of about three cases per 100,000 people.

Infectious infections are one of the most common causes of splenic enlargement. Splenomegaly is treated therapeutically by addressing the underlying reasons. One of the important factors expected to boost the antibiotic therapy segment of the global market during the projected period is the high prevalence of various bacterial, fungal, and viral infectious disorders. Due to the increased prevalence of autoimmune disorders, such as rheumatoid arthritis, inflammatory bowel disease, gout, and multiple sclerosis, immunosuppressive therapy is expected to be the fastest-growing segment of the global splenomegaly therapeutics market over the forecast period.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Pfizer Inc., Teva Pharmaceutical Industries, Novartis AG and Thermo Fisher Scientific among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Splenomegaly Therapeutics Market by Segment

By Treatment 

• Common Antibiotic Therapy

• Chemotherapy

• Immunosuppressive Therapy

• Vaccination  

By Distribution Channel 

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy 

Global Splenomegaly Therapeutics Market by Region